Questions about ASTRO 2026

Are there any contraindications to Pluvicto therapy you personally use, given that there are none directly provided by the manufacturer?

This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidisciplinary Radiopharmaceutical Symposium. This ...

2 Answers available

In mCRPC patients who had an initial response to Pluvicto but progress within 12 months, where do you position PSMA radioligand retreatment relative to other next-line systemic options in your sequencing strategy?

This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidisciplinary Radiopharmaceutical Symposium. This ...

1 Answer available

What criteria are you using for retreatment with Pluvicto (Lu-177) in those who maintain a good performance status and appropriate lab work?

This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidisciplinary Radiopharmaceutical Symposium. This ...

2 Answers available

Does the possibility of future Lu-177–PSMA therapy change your current threshold to offer earlier metastasis-directed RT in oligometastatic prostate cancer?

Would the extent of marrow exposure at the treatment site affect your decision-making? This question is part of our collaboration with ASTRO to highl...

2 Answers available

How do you sequence Pluvicto vs docetaxel in a fit, chemotherapy-naïve patient with high-volume PSMA-avid mCRPC progressing on an ARPI?

This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidisciplinary Radiopharmaceutical Symposium. This ...

1 Answer available

Can you give Pluvicto with concurrent palliative EBRT?

If so, do you modify your external beam dose? This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidi...

2 Answers available

When selecting mCRPC patients for Pluvicto, which baseline variables do you find most useful or predictive of potential hematologic toxicity?

e.g., baseline counts, prior taxane exposure, prior EBRT, imaging evidence of marrow-involving disease. This question is part of our collaboration wi...

1 Answer available

Do you modify dosing and monitoring of Lu-177–PSMA therapy for patients with prior large-field RT involving substantial active marrow compared with patients who only had focal bone SBRT?

This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidisciplinary Radiopharmaceutical Symposium. This ...

1 Answer available

For patients starting Pluvicto, do you have patients stop their ARPI?

This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidisciplinary Radiopharmaceutical Symposium. This ...

3 Answers available

ASTRO 2026

Questions discussed in this category

Papers discussed in this category

Related Topics